•
Jun 30, 2021

AbCellera Q2 2021 Earnings Report

Reported strong growth across key performance indicators related to the partnership business, including new programs under contract, program starts, and new molecules in the clinic.

Key Takeaways

AbCellera reported Q2 2021 financial results with a total revenue of $27.6 million, up from $11 million in Q2 2020. The company incurred a net loss of $2.3 million, compared to net earnings of $6.7 million in Q2 2020.

Earned $27.6 million in total revenue, including $22.2 million in milestones and royalties.

Incurred net loss of $2.3 million, compared to generating net earnings of $6.7 million in Q2 2020.

Added 19 programs under contract with four new partners, resulting in a cumulative total of 138 programs under contract with 33 different partners.

Confirmed three new molecules advanced into the clinic, bringing the cumulative total to four.

Total Revenue
$27.6M
Previous year: $11.2M
+146.2%
EPS
-$0.01
Previous year: $0.3
-103.3%
Programs under contract
138
Previous year: 76
+81.6%
Gross Profit
$24M
Previous year: $2.08M
+1053.2%
Cash and Equivalents
$793M
Free Cash Flow
$121M
Previous year: $22.3M
+442.7%
Total Assets
$1.15B

AbCellera

AbCellera

AbCellera Revenue by Segment

Revenue & Expenses

Visualization of income flow from segment revenue to net income